ANGEVOUR darbepoetin alfa (rch) 15 microgram/0.38mL injection syringe with automatic needle guard Австралія - англійська - Department of Health (Therapeutic Goods Administration)

angevour darbepoetin alfa (rch) 15 microgram/0.38ml injection syringe with automatic needle guard

amgen australia pty ltd - darbepoetin alfa, quantity: 39.47 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; sodium chloride; dibasic sodium phosphate; polysorbate 80 - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ANGEVOUR darbepoetin alfa (rch) 10 microgram/0.4mL injection syringe Австралія - англійська - Department of Health (Therapeutic Goods Administration)

angevour darbepoetin alfa (rch) 10 microgram/0.4ml injection syringe

amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; dibasic sodium phosphate; polysorbate 80; monobasic sodium phosphate monohydrate - angevour is indicated for the treatment of anaemia associated with chronic renal failure (crf). angevour is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP darbepoetin alpha (rch) 60 microgram/0.3mL injection syringe Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alpha (rch) 60 microgram/0.3ml injection syringe

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

ARANESP SOLUTION Канада - англійська - Health Canada

aranesp solution

amgen canada inc - darbepoetin alfa - solution - 15mcg - darbepoetin alfa 15mcg - hematopoietic agents

ARANESP SOLUTION Канада - англійська - Health Canada

aranesp solution

amgen canada inc - darbepoetin alfa - solution - 25mcg - darbepoetin alfa 25mcg - hematopoietic agents

ARANESP        -(HSA-FREE) SOLUTION Канада - англійська - Health Canada

aranesp -(hsa-free) solution

amgen canada inc - darbepoetin alfa - solution - 40mcg - darbepoetin alfa 40mcg - hematopoietic agents

ARANESP SOLUTION Канада - англійська - Health Canada

aranesp solution

amgen canada inc - darbepoetin alfa - solution - 60mcg - darbepoetin alfa 60mcg - hematopoietic agents

ARANESP        -(HSA-FREE) SOLUTION Канада - англійська - Health Canada

aranesp -(hsa-free) solution

amgen canada inc - darbepoetin alfa - solution - 100mcg - darbepoetin alfa 100mcg - hematopoietic agents

ARANESP        -(HSA-FREE) SOLUTION Канада - англійська - Health Canada

aranesp -(hsa-free) solution

amgen canada inc - darbepoetin alfa - solution - 200mcg - darbepoetin alfa 200mcg - hematopoietic agents

ARANESP SOLUTION Канада - англійська - Health Canada

aranesp solution

amgen canada inc - darbepoetin alfa - solution - 325mcg - darbepoetin alfa 325mcg - hematopoietic agents